Entries by Maren Kühr

Richter-Helm triples capacity at Bovenau site

Richter-Helm, a leading steadily growing Germany-based contract development and manufacturing organization (CDMO), offers excellent services in the continuously growing market of pharmaceutical biotechnology. Two additional bioreactors with capacities of 300 litres and 1,500 litres for microbial production will be added. This includes also the establishment of mid- and downstream processing and supporting utilities on a total area of about 10,000 m².

Pandemic demand drives skills and production gap

The life sciences industry stepped up its pace in the last year to rapidly fill a void in the fight against COVID-19. Solis BioDyne is one of many companies that have experienced a dramatic increase in demand for its solutions during the pandemic – especially for products used in COVID-19 diagnostic tests. The company knew it needed to ramp up production. And time was not on their side.

Biopharma partnerships – a key to success

Innovators at Rentschler Biopharma are continuously developing new processes for biopharmaceutical production to tackle life-threatening diseases. Two of them, Dr Birgit Ehrenberg, Process Manager, and Monika Häußler, Quality Control (QC) Manager, shared insights into their latest projects and how close collaboration with chromatography experts from Tosoh Bioscience helped them develop robust, scalable, and economically viable downstream processes, as well as corresponding reliable bioanalytical methods.

Market trends and the biopharma evolution

With many complex factors affecting a therapeutic candidate’s chances of approval, partnering with a qualified service provider can be the most effective way to produce material for clinical trials. Outsourcing allows you to delay critical capacity decisions until the fate of your molecule is more certain — but, how do you ensure this approach results in a successful process that’s delivered within your target timeline?

Startup Labs at the Vienna BioCenter

The Vienna Business Agency has set up affordable and flexible Startup Labs at the Vienna BioCenter. This will speed up the evaluation and implementation of new business ideas in biotechnology by the next coming generation of bio-entrepreneurs. Key assets include close proximity to outstanding academic research and highly successful innovators as well as access to cutting-edge research infrastructure.

Searching for an effective treatment for COVID-19

Apogenix has entered the global fight against COVID-19. Lead immunotherapy candidate asunercept (APG101) is being evaluated in two clinical phase II trials in patients with COVID-19 disease. With its unique mechanism of action, asunercept may reduce lymphopenia, lung epithelial damage, and inflammatory cell death in COVID-19 patients, thus providing a unique therapeutic approach for this devastating disease.

A Comprehensive Tool Set for COVID-19 Research

Sino Biological is a world-leading manufacturer of recombinant protein and antibody reagents for life science researches and drug discoveries. In response to the current COVID-19 pandemic, we have developed a series of active reagents (virus proteins, antibodies, and pseudoviruses) to facilitate serologic tests and anti-viral drug developments.

Complete toolkit for SARS-CoV-2 antigen test

Sino Biological Inc. has developed a complete toolkit for SARS-CoV-2 antigen tests, including a large panel of antibodies specific to SARS-CoV-2 S&N proteins and antibody pairs that can be used to assemble detection assays for the corresponding antigen.